Literature DB >> 19430491

The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.

A Astanehe1, M R Finkbeiner, P Hojabrpour, K To, A Fotovati, A Shadeo, A L Stratford, W L Lam, I M Berquin, V Duronio, S E Dunn.   

Abstract

PIK3CA, which codes for the p110alpha catalytic subunit of phosphatidylinositol-3-kinase (PI3K), is implicated as an oncogene. Despite importance of PIK3CA in cancer, little is known about what drives up its expression in tumor cells. We recently characterized the PIK3CA promoter and reported that it is transcriptionally silenced by the tumor suppressor protein p53. In the present study, we demonstrate that PIK3CA can be induced by the oncogenic transcription factor Y-box binding protein-1 (YB-1). Three YB-1-responsive elements were identified on the PIK3CA promoter using chromatin immunoprecipitation and electrophoretic mobility shift assays. Interestingly, silencing YB-1 with siRNA in models of basal-like breast cancer decreased p110alpha protein levels regardless of whether PIK3CA was wild type, amplified or mutated. This decrease in p110alpha led to a reduction in PI3K activity and the downstream signaling primarily through p90 ribosomal S6 kinase and S6 ribosomal protein. Disruption in PIK3CA-dependent signaling suppressed cellular invasion correlative with loss of urokinase plasminogen activator (uPA). Similarly, silencing YB-1 suppressed invasion and uPA production however this was reversible through the introduction of constitutively active PIK3CA. In conclusion, YB-1 is the first reported oncogene to induce the expression of PIK3CA through transcriptional control of its promoter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430491     DOI: 10.1038/onc.2009.81

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.

Authors:  Karen To; Abbas Fotovati; Kristen M Reipas; Jennifer H Law; Kaiji Hu; Jing Wang; Arezoo Astanehe; Alastair H Davies; Lawrence Lee; Anna L Stratford; Afshin Raouf; Pauline Johnson; Isabelle M Berquin; Hans-Dieter Royer; Connie J Eaves; Sandra E Dunn
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  p53 Loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance.

Authors:  Bhushan Thakur; Pritha Ray
Journal:  Mol Oncol       Date:  2016-06-29       Impact factor: 6.603

3.  Crystal structure of a Y-box binding protein 1 (YB-1)-RNA complex reveals key features and residues interacting with RNA.

Authors:  Xiao-Juan Yang; Hong Zhu; Shi-Rong Mu; Wen-Juan Wei; Xun Yuan; Meng Wang; Yanchao Liu; Jingyi Hui; Ying Huang
Journal:  J Biol Chem       Date:  2019-06-03       Impact factor: 5.157

4.  Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription.

Authors:  Shi-Jiang Deng; Heng-Yu Chen; Zeng Ye; Shi-Chang Deng; Shuai Zhu; Zhu Zeng; Chi He; Ming-Liang Liu; Kang Huang; Jian-Xin Zhong; Feng-Yu Xu; Qiang Li; Yang Liu; Chun-You Wang; Gang Zhao
Journal:  Oncogene       Date:  2018-07-03       Impact factor: 9.867

5.  The p63 protein isoform ΔNp63α modulates Y-box binding protein 1 in its subcellular distribution and regulation of cell survival and motility genes.

Authors:  Antonella Di Costanzo; Annaelena Troiano; Orsola di Martino; Andrea Cacace; Carlo F Natale; Maurizio Ventre; Paolo Netti; Sergio Caserta; Alessandra Pollice; Girolama La Mantia; Viola Calabrò
Journal:  J Biol Chem       Date:  2012-07-11       Impact factor: 5.157

6.  The N-terminal domain of y-box binding protein-1 induces cell cycle arrest in g2/m phase by binding to cyclin d1.

Authors:  Payal Khandelwal; Mythili K Padala; John Cox; Ramareddy V Guntaka
Journal:  Int J Cell Biol       Date:  2010-04-14

7.  Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.

Authors:  Karsten Jürchott; Ralf-Jürgen Kuban; Till Krech; Nils Blüthgen; Ulrike Stein; Wolfgang Walther; Christian Friese; Szymon M Kiełbasa; Ute Ungethüm; Per Lund; Thomas Knösel; Wolfgang Kemmner; Markus Morkel; Johannes Fritzmann; Peter M Schlag; Walter Birchmeier; Tammo Krueger; Silke Sperling; Christine Sers; Hans-Dieter Royer; Hanspeter Herzel; Reinhold Schäfer
Journal:  PLoS Genet       Date:  2010-12-02       Impact factor: 5.917

Review 8.  Targeting the Y/CCAAT box in cancer: YB-1 (YBX1) or NF-Y?

Authors:  D Dolfini; R Mantovani
Journal:  Cell Death Differ       Date:  2013-03-01       Impact factor: 15.828

9.  Cytokines secreted by macrophages isolated from tumor microenvironment of inflammatory breast cancer patients possess chemotactic properties.

Authors:  Mona M Mohamed; Eslam A El-Ghonaimy; Mohamed A Nouh; Robert J Schneider; Bonnie F Sloane; Mohamed El-Shinawi
Journal:  Int J Biochem Cell Biol       Date:  2013-11-26       Impact factor: 5.085

10.  Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway.

Authors:  Wen-Fei Xu; Yi-Cong Ma; Hou-Shi Ma; Long Shi; Hang Mu; Wen-Bin Ou; Jie Peng; Ting-Ting Li; Tianyi Qin; Hai-Meng Zhou; Xue-Qi Fu; Xu-Hui Li
Journal:  Cell Cycle       Date:  2019-11-12       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.